Terms: = Breast cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169
454 results:
1. LncRNA DLG5-AS1 facilitates breast cancer cell proliferation and invasion by promoting ezh2-mediated transcriptional silencing of SFRP1.
Cai Y; Liu Y; Sun Y; Ren Y
Arch Biochem Biophys; 2024 Jun; 756():110018. PubMed ID: 38677505
[TBL] [Abstract] [Full Text] [Related]
2. siRNA treatment targeting integrin α11 overexpressed via ezh2-driven axis inhibits drug-resistant breast cancer progression.
Chaudhary P; Yadav K; Lee HJ; Kang KW; Mo J; Kim JA
Breast Cancer Res; 2024 Apr; 26(1):72. PubMed ID: 38664825
[TBL] [Abstract] [Full Text] [Related]
3. Hypoxia-activated XBP1s recruits HDAC2-ezh2 to engage epigenetic suppression of ΔNp63α expression and promote breast cancer metastasis independent of HIF1α.
Chen H; Yu S; Ma R; Deng L; Yi Y; Niu M; Xu C; Xiao ZJ
Cell Death Differ; 2024 Apr; 31(4):447-459. PubMed ID: 38413797
[TBL] [Abstract] [Full Text] [Related]
4. ezh2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract] [Full Text] [Related]
5. A Metabolic-Epigenetic Mechanism Directs Cell Fate and Therapeutic Sensitivity in breast cancer.
Bernard MJ; Goldstein AS
Cancer Res; 2024 May; 84(9):1382-1383. PubMed ID: 38330100
[TBL] [Abstract] [Full Text] [Related]
6. Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance.
James JL; Taylor BC; Axelrod ML; Sun X; Guerin LN; Gonzalez-Ericsson PI; Wang Y; Sanchez V; Fahey CC; Sanders ME; Xu Y; Hodges E; Johnson DB; Balko JM
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38315170
[TBL] [Abstract] [Full Text] [Related]
7. Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative breast cancer.
Gardi N; Chaubal R; Parab P; Pachakar S; Kulkarni S; Shet T; Joshi S; Kembhavi Y; Chandrani P; Quist J; Kowtal P; Grigoriadis A; Sarin R; Govindarajan R; Gupta S
Cancer Res Commun; 2024 Feb; 4(2):404-417. PubMed ID: 38315150
[TBL] [Abstract] [Full Text] [Related]
8. Discovery of a novel, highly potent ezh2 PROTAC degrader for targeting non-canonical oncogenic functions of ezh2.
Velez J; Dale B; Park KS; Kaniskan HÜ; Yu X; Jin J
Eur J Med Chem; 2024 Mar; 267():116154. PubMed ID: 38295690
[TBL] [Abstract] [Full Text] [Related]
9. Deciphering the Immune Microenvironment at the Forefront of Tumor Aggressiveness by Constructing a Regulatory Network with Single-Cell and Spatial Transcriptomic Data.
Xu K; Yu D; Zhang S; Chen L; Liu Z; Xie L
Genes (Basel); 2024 Jan; 15(1):. PubMed ID: 38254989
[TBL] [Abstract] [Full Text] [Related]
10. Refining breast cancer biomarker discovery and drug targeting through an advanced data-driven approach.
Rakhshaninejad M; Fathian M; Shirkoohi R; Barzinpour F; Gandomi AH
BMC Bioinformatics; 2024 Jan; 25(1):33. PubMed ID: 38253993
[TBL] [Abstract] [Full Text] [Related]
11. MiR-600 mediates ezh2/RUNX3 signal axis to modulate breast cancer cell viability and sorafenib sensitivity.
Zhao Q; Li D; Feng J; Jinsihan D
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23613. PubMed ID: 38229326
[TBL] [Abstract] [Full Text] [Related]
12. Bruceine D and Narclasine inhibit the proliferation of breast cancer cells and the prediction of potential drug targets.
Chen X; Li H
PLoS One; 2024; 19(1):e0297203. PubMed ID: 38215156
[TBL] [Abstract] [Full Text] [Related]
13. Design, synthesis, and evaluation of VHL-based ezh2 degraders for breast cancer.
Xiao B; Shi Z; Liu J; Huang Q; Shu K; Liu F; Zhi C; Zhang D; Wu L; Yang S; Zeng X; Fan T; Liu Z; Jiang Y
Bioorg Chem; 2024 Feb; 143():107078. PubMed ID: 38181661
[TBL] [Abstract] [Full Text] [Related]
14. Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer.
Zhang Y; Wu MJ; Lu WC; Li YC; Chang CJ; Yang JY
Cell Metab; 2024 Jan; 36(1):193-208.e8. PubMed ID: 38171333
[TBL] [Abstract] [Full Text] [Related]
15. Dual target PARP1/ezh2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.
Li X; Wang C; Li S; Yin F; Luo H; Zhang Y; Luo Z; Chen Y; Wan S; Kong L; Wang X
Eur J Med Chem; 2024 Feb; 265():116054. PubMed ID: 38134746
[TBL] [Abstract] [Full Text] [Related]
16. ezh2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract] [Full Text] [Related]
17. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (ezh2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract] [Full Text] [Related]
18. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
Zhang J; Li C; Sun L; Sun D; Zhao T
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
[TBL] [Abstract] [Full Text] [Related]
19. Phosphorylation of ezh2 differs HER2-positive breast cancer invasiveness in a site-specific manner.
Yu F; Li L; Zhang M; Sun S
BMC Cancer; 2023 Oct; 23(1):948. PubMed ID: 37803297
[TBL] [Abstract] [Full Text] [Related]
20. SND1, a novel co-activator of HIF1α, promotes tumor initiation in PyMT-induced breast tumor.
Hu L; Zeng Y; Xin L; Yang J
FEBS J; 2023 Dec; 290(24):5759-5772. PubMed ID: 37622244
[TBL] [Abstract] [Full Text] [Related]
[Next]
